Capricor Therapeutics, Inc. (CAPR) Revenue History
Annual and quarterly revenue from 1999 to present
CAPR Revenue Over Time (1999–2025)
CAPR Revenue Growth History
4 of 18 years with positive growth- FY1999 revenue growth
- N/A
- FY2000 revenue growth
- N/A
- FY2001 revenue growth
- N/A
- FY2002 revenue growth
- N/A
- FY2003 revenue growth
- -81.0%
- FY2004 revenue growth
- -100.0%
- FY2005 revenue growth
- N/A
- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- -73.4%
- FY2008 revenue growth
- -100.0%
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- -85.6%
- FY2013 revenue growth
- +157.4%
- FY2014 revenue growth
- +728.0%
- FY2015 revenue growth
- -9.4%
- FY2016 revenue growth
- -15.5%
- FY2017 revenue growth
- -16.4%
- FY2018 revenue growth
- -37.3%
- FY2019 revenue growth
- -39.9%
- FY2020 revenue growth
- -69.1%
- FY2021 revenue growth
- -21.1%
- FY2022 revenue growth
- +941.8%
- FY2023 revenue growth
- +886.8%
- FY2024 revenue growth
- -11.5%
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $0 | -100.0% |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $11.1M | -7.9% |
| Q3 2024 | $2.3M | -63.4% |
| Q2 2024 | $4.0M | +1.4% |
Multi-year avg. share of annual revenue by fiscal quarter
CAPR Revenue Analysis (1999–2025)
Current Revenue & Growth
As of June 23, 2026, Capricor Therapeutics, Inc. (CAPR) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
CAPR's historical revenue data shows various trends over time. Capricor Therapeutics, Inc.'s highest annual revenue of $25.2 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including SRPT (-2.2% YoY), CRSP (-88.9% YoY), and EXEL (+3.3% YoY). Compare CAPR vs SRPT →
CAPR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| $0 | - | - | - | ||
| $2.2B | -2.2% | +32.4% | -29.9% | ||
| $4M | -88.9% | +37.3% | -16191.4% | ||
| $2.3B | +3.3% | +18.6% | 37.6% | ||
| $634M | +20.0% | +19.4% | 5.4% | ||
| $673M | +13.3% | +19.9% | -79.5% |
CAPR Historical Revenue Data (1999–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $-108,142,130 | - |
| 2024 | $22.3M | -11.5% | $-27,698,120 | -124.4% | $-42,564,842 | -191.1% |
| 2023 | $25.2M | +886.8% | $-11,269,973 | -44.8% | $-24,077,859 | -95.6% |
| 2022 | $2.6M | +941.8% | $-19,265,480 | -755.1% | $-29,697,383 | -1163.9% |
| 2021 | $245K | -21.1% | $245K | 100.0% | $-20,938,442 | -8549.9% |
| 2020 | $310K | -69.1% | $310K | 100.0% | $-13,689,971 | -4412.6% |
| 2019 | $1.0M | -39.9% | $-4,136,777 | -411.6% | $-7,733,888 | -769.5% |
| 2018 | $1.7M | -37.3% | $1.7M | 100.0% | $-15,327,000 | -917.2% |
| 2017 | $2.7M | -16.4% | $2.7M | 100.0% | $-12,862,000 | -482.4% |
| 2016 | $3.2M | -15.5% | $-12,043,000 | -377.5% | $-16,977,000 | -532.2% |
| 2015 | $3.8M | -9.4% | $-8,240,000 | -218.2% | $-12,612,000 | -334.0% |
| 2014 | $4.2M | +728.0% | $-3,001,000 | -72.0% | $-6,018,000 | -144.4% |
| 2013 | $503K | +157.4% | $503K | 100.0% | $-6,903,000 | -1371.7% |
| 2012 | $196K | -85.6% | $196K | 100.0% | $-2,440,000 | -1248.1% |
| 2011 | $1.4M | - | $1.4M | 100.0% | $-4,899,000 | -361.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
Is CAPR's revenue growth accelerating or slowing?
CAPR TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CAPR's revenue history from 1999 to 2026?
Capricor Therapeutics, Inc. (CAPR) revenue history spans 1999 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CAPR's long-term revenue growth rate (CAGR)?
Capricor Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CAPR.
Why does CAPR's quarterly revenue fluctuate?
CAPR quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Capricor Therapeutics, Inc.'s revenue data from 1999 to 2026 shows full historical quarterly detail on this page.
How is CAPR's revenue distributed by segment?
CAPR reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CAPR's revenue compare to industry peers?
Capricor Therapeutics, Inc. (CAPR) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.